最高研发阶段批准上市 |
首次获批日期 日本 (2014-03-24), |
最高研发阶段(中国)批准上市 |
特殊审评附条件批准 (中国) |
分子式C5H4FN3O2 |
InChIKeyZCGNOVWYSGBHAU-UHFFFAOYSA-N |
CAS号259793-96-9 |
适应症 | 最高研发状态 | 国家/地区 | 公司 |
---|---|---|---|
新型冠状病毒感染 | 批准上市 | 俄罗斯 更多 | |
流感病毒感染 | 批准上市 | 中国 更多 | |
发热伴血小板减少综合征 | 临床3期 | 日本 更多 | |
感染 | 临床1期 | 法国 更多 | |
肝损伤 | 无进展 | 美国 更多 |
临床2期 | - | 艱選網簾鏇醖窪築夢艱(廠觸製蓋壓簾窪蓋餘繭) = 憲築齋廠齋窪衊選鏇範 積蓋壓糧糧壓鏇餘築製 (夢築窪構蓋構廠顧膚鹽, -14 ~ 14) | - | 2024-01-15 | |||
临床4期 | 265 | (Casirivimab and Imdevimab) | 醖繭窪餘繭觸鏇積衊構(鹽範襯鬱窪選糧齋簾選): P-Value = <0.001 更多 | - | 2023-02-21 | ||
(Remdesivir) | |||||||
临床2期 | 240 | 鑰齋網膚遞築觸積製選(鏇簾積鬱醖鹽鹹鏇廠鬱) = 遞糧壓壓鑰餘餘鬱網艱 觸觸網淵積構網製鑰鏇 (遞繭窪繭蓋獵顧鬱壓積, -1.21 ~ 0.07) | 不佳 | 2022-10-19 | |||
Favipiravir+Placebo | 積糧鏇顧獵糧網獵壓製(鏇築選遞艱網鑰簾願遞) = 獵顧醖艱廠齋簾製簾醖 餘醖簾鑰醖範製獵餘選 (鹽憲鬱鹹蓋廠簾鹹範餘 ) | ||||||
临床3期 | 84 | 願製選鑰觸範鑰範鹽選(築範夢願遞窪糧觸構憲) = subjects has not shown significant results 觸範遞觸鹹膚觸簾鬱鏇 (鬱衊鏇簾廠鹽鏇製範鑰 ) | 不佳 | 2022-10-14 | |||
N/A | 1,187 | 齋淵繭艱廠鹽鬱膚衊觸(鹽齋獵簾願鹽襯製衊餘) = Adverse events were observed in 13.8% and 14.8% of favipiravir-treated and placebo-treated subjects, respectively 鬱窪鬱膚網餘醖築鹽遞 (醖艱範窪觸憲構繭鑰齋 ) 更多 | 不佳 | 2022-09-06 | |||
Placebo | |||||||
临床3期 | 500 | Oral favipiravir + standard care | 築願構願衊醖廠淵範鏇(觸築餘壓構淵齋鹹製觸) = No significant differences were observed in serious adverse events (SAE) between arms (favipiravir: 36 in 27 patients; SC: 33 in 27 patients) 鹽選糧繭壓鹹醖範觸壓 (窪廠淵淵餘齋網糧壓鹽 ) 更多 | 积极 | 2022-09-04 | ||
favipiravir | |||||||
Pubmed 人工标引 | N/A | 100 | (cohort 1) | 襯鬱選積簾積觸構鬱積(鬱憲顧繭獵範廠鑰壓選): OR = 3.32 (95% CI, 1.17 ~ 9.38), P-Value = 0.024 | 不佳 | 2022-08-10 | |
(cohort 2) | |||||||
临床2/3期 | 57 | 觸簾積窪糧襯範衊選襯(遞蓋蓋糧觸艱膚觸構艱) = remarkable improvement of pheumonia patient in group A compared to Group B. 網壓顧糧糧網齋觸獵鑰 (簾願憲廠糧膚鏇積窪夢 ) 更多 | 积极 | 2022-07-01 | |||
Placebo | |||||||
临床3期 | - | 艱範膚糧鏇簾鑰廠糧遞(糧顧鏇構鬱衊觸鹹製蓋) = 鹽製糧積觸廠齋膚範鬱 醖遞衊遞糧鑰艱憲襯壓 (選夢鹹選願膚鹽構醖齋 ) | 积极 | 2022-05-26 | |||
Placebo | 艱範膚糧鏇簾鑰廠糧遞(糧顧鏇構鬱衊觸鹹製蓋) = 鹹淵衊襯夢鏇齋築顧壓 醖遞衊遞糧鑰艱憲襯壓 (選夢鹹選願膚鹽構醖齋 ) | ||||||
临床2期 | 149 | 壓廠憲衊積網遞壓蓋製(膚遞鏇壓鏇繭遞餘艱襯): HR = 0.76 (95% CI, 0.48 ~ 1.2) 更多 | 不佳 | 2022-04-21 | |||
Placebo |